{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.39","value":"7.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"ADC"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.27","value":"4.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"TAb"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10800","value":"28900"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"MMAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Vss was derived from the PK blood samples collected.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 1.25 mg/kg of body weight enfortumab vedotin by IV infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.","id":"OG000","title":"Enfortumab Vedotin 1.25 mg/kg"}],"paramType":"MEAN","populationDescription":"PKAS population with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)","title":"PK of ADC, TAb, MMAE in Serum: Volume of Distribution at Steady State (Vss)","type":"PRIMARY","unitOfMeasure":"Liters"}